You have accessJournal of UrologySurgical Technology & Simulation: Instrumentation & Technology II (PD23)1 Apr 2020PD23-09 INITIAL EXPERIENCE OF NEW SENHANCE ROBOTIC SYSTEM IN UROLOGIC SURGERY LunHsiang Yuan*, ShiWei Huang, and YuWen Huang LunHsiang Yuan*LunHsiang Yuan* More articles by this author , ShiWei HuangShiWei Huang More articles by this author , and YuWen HuangYuWen Huang More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000873.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The use of robotic surgeries is increasing in urologic field. Recently, the Senhance robotic system, a novel robotic platform was introduced on the market. It is based on standard laparoscopic surgery, equipped with haptic feedback and eye tracking system. Currently, the surgical platform is only used in general surgery, colo-rectal surgery and gynecological surgery. This study describes the initial, single center experience, evaluating the feasibility and safety of the new robotic system in performing urologic surgeries. METHODS: From July 2019 to October 2019, total 34 patients undergoing urologic surgery with Senhance robotic system were collected. Their peri-operative data were analyzed. Indications for surgery include inguinal hernia, stone disease, ureteral stricture, renal cell carcinoma, urothelial carcinoma and prostate cancer. RESULTS: The median age was 69 years-old (42-85). Surgical procedures include 15 cases (44.1%) hernioplasty, 6 cases (17.6%) radical prostatectomy, 5 cases (14.7%) ureterolithotomy and ureteral reconstruction, 2 cases (5.8%) partial nephrectomy, 2 cases (5.8) adrenalectomy, 2 cases (5.8%) renal cysts unroofing, 1 case (2.4%) abdominal exploration for cryptorchidism, 1 case (2.4%) nephroureterectomy and bladder cuff excision. Nine cases (26.4%) were operated for malignant diseases (6 adenocarcinoma of prostate, 2 renal cell carcinoma, and 1 urothelial carcinoma) The median docking time was 10 min (8-30). The median operative time was 125 min (93-325). The median time to discharge was 7 days (3-10). The incidence of post-operative complications was 20.5% (Clavien-Dindo I/II- 7 patients) . There's no Clavien-Dindo III/IV complications. No patient was re-admitted and no patient require re-operation. CONCLUSIONS: The results showed Senhance surgical robotic system could be adopted in urologic surgery. It is safe and feasible, and could performed most urologic procedures. The learning curve is quick and its special advantage offer urologist more choices of robotic surgery. More clinical data are needed to determine whether it could provide any other benefits. Source of Funding: nil © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e467-e467 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information LunHsiang Yuan* More articles by this author ShiWei Huang More articles by this author YuWen Huang More articles by this author Expand All Advertisement PDF downloadLoading ...
Read full abstract